Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – online resources
    • IMPACT
      • Workshops
      • IMPACT – online resources
      • IMPACT news
      • IMPACT partners and sponsors
    • SPECC
      • Workshops
      • Online resources
      • SPECC Partners and Sponsors
      • SPECC News
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • PELT
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
        • How your donations are spent
    • Events and Challenges
    • Leaving a Legacy
    • Fundraising
      • Our fundraisers
      • Fundraising pack
      • Fundraising opportunities
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Online Shop
  • Events
  • Contact us

Pelican Cancer Foundation launches national programme to fight bowel cancer

July 19, 2017 by pelicanadmin

This national programme will help specialists identify bowel cancer earlier, improve precision treatment and help patients live better for longer, wherever they live. As well as potentially improving outcomes for over 6,200 patients, it will also support local cancer services and could help save the NHS up to £34 million in the long term. (I)

Bowel cancer is the second most common cause of cancer death in the UK (II). The earlier bowel cancer is diagnosed and treated, the better the outcome for patients. Increased public awareness and improved screening have resulted in more patients being diagnosed at an earlier stage of their disease, but there is variability across the UK in the diagnosis and management of early stage cancer, with under- and over-treatment a significant global issue.

As part of the SPECC programme, six core members of all 164 Colorectal Cancer Multi-Disciplinary Teams (MDTs) in England and Wales will be invited to attend a one day workshop on the complex topic of treatment for small (T1) tumours and significant polyps. Hosted across England and Wales over 2015-2017, these workshops will bring together surgeons, radiologists, gastroenterologists, pathologists and clinical nurse specialists to look at the evidence, discuss methods for early diagnosis and treatment and develop informed decision-making for the whole bowel cancer team. Teams will be encouraged to develop their local treatment strategies as well as regional partnerships to help provide consistent treatment options across England and Wales.

The clinical lead for SPECC is Mr Brendan Moran (Surgeon at Basingstoke) with Sarah Crane at the Pelican Cancer Foundation. The eminent steering group includes Professors Wendy Atkin (Epidemiologist at Imperial), Brian Saunders (Gastroenterologist at St Marks), Gina Brown (Radiologist at Royal Marsden), Phil Quirke (Pathologist at Leeds) and Bob Steele (Surgeon at Dundee). Other leaders in the field, from hospitals around England and Wales, will help deliver the programme.

Pelican Cancer Foundation has an exceptional reputation for developing high-impact national and international meetings to improve patient care for cancer patients. Pelican developed and ran LOREC – a previous national programme to improve outcomes in patients with low rectal cancer through enhancing patient-centred decision-making for MDTs. This was attended by 1,200 cancer specialists. Its concepts and strategies influenced 90% of all English colorectal MDTs and had a global impact in the field. (III)

Commenting on the SPECC programme, Sarah Crane, CEO of Pelican Cancer Foundation, said “Our work is all about making a real difference for today’s cancer patients, both in terms of survival and quality of life. Successful roll-out of this new programme will see more consistent treatment options for bowel cancer patients wherever they live. We are very excited to be launching this vital programme and can’t wait to see the impact it will have on the daily practice of cancer specialists nation-wide. We want to thank everyone who has worked so tirelessly with us to make this programme happen.”

SPECC is endorsed by The Association of Coloproctology of Great Britain and Ireland, Beating Bowel Cancer, Bowel Cancer UK, Hampshire Hospitals NHS Foundation Trust, The Royal College of Pathologists and kindly supported by industry sponsors, including (from September 2015 to June 2016) Gold Sponsors Exact Sciences, manufacturer of the stool DNA test Cologuard.

For further information on the SPECC programme, go to www.pelicancancer.org/specc
For further information about the Pelican Cancer Foundation, go to www.pelicancancer.org
Twitter: @Pelican_Cancer #SPECCPOLYP

Sources

I. Saving lives, averting costs: An analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer – A report prepared for Cancer Research UK, Incisive Health, September 2014

II. Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/common-cancers-compared#heading-Zero, Accessed October 2015

III. Moran et al., The English National Low Rectal Cancer Development Programme: Key messages and future perspectives; Colorectal Disease, 2013, The Association of Coloproctology of Great Britain and Ireland 16, 173-178

Pelican Cancer Foundation, The Ark, Dinwoodie Drive, Basingstoke, Hants RG24 9NN | Tel: 01256 314 746 |
admin@pelicancancer.org | www.pelicancancer.org | Registered charity 1141911 (England and Wales),
company limited by guarantee 7264864 (England). Registered office as above.

Filed Under: Uncategorized

Pelican Cancer FoundationFollow

Pelican Cancer Foundation
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
22 Dec

We would like to wish you all a very Merry Christmas and a peaceful New Year - especially to all the wonderful key workers, who will be working throughout. 🎄🥂🎁

Reply on Twitter 1341352794255593477Retweet on Twitter 1341352794255593477Like on Twitter 13413527942555934771Twitter 1341352794255593477
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
7 Dec

👏

Reply on Twitter 1335864743752589312Retweet on Twitter 1335864743752589312Like on Twitter 13358647437525893122Twitter 1335864743752589312
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
5 Dec

Let loved ones know that you are thinking of them over the festive period and send a handwritten Christmas card. Order your Christmas cards from us at http://www.pelicancancer.org/shop. 🎄(Royal Mail’s latest recommended posting dates are 18th Dec (2nd Class) and 21st Dec (1st Class). 🎄

Reply on Twitter 1335126762079068160Retweet on Twitter 1335126762079068160Like on Twitter 1335126762079068160Twitter 1335126762079068160
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in